SwingTrade Member Forum

[RIGATONI]

~DNAP News...

I am not in anymore.


DNAPrint(TM) Participates in the TBTF and BioFlorida Tampa Bay Partnering Conference Thursday, April 1, 2004
Wednesday March 17, 1:29 pm ET


SARASOTA, Fla., March 17 /PRNewswire-FirstCall/ -- DNAPrint's CEO and President is presenting at the combined Tampa Bay Technology Forum and BioFlorida Tampa Bay partnering conference on April 1, 2004 at the Hyatt Sarasota, 1000 Blvd. of the Arts, Sarasota, Florida. The presentation will include a description of DNAPrint(TM)'s technology and market applications. The presentation will highlight the four market segments in which DNAPrint(TM) applies its proprietary Single Nucleotide Polymorphism (SNP) screening technology: 1) genealogy; featuring its latest released product ANCESTRYbyDNA(TM) 2.5 used by genealogists and families to help understand their genetic heritage; 2) forensics; featuring its flagship product DNAWitness(TM) 2.0, which was introduced and first used in the first quarter of 2003 and has since helped detectives and investigators in two high-profile cases, the Louisiana serial killer case (2003) and the Concord, California case; 3) pharmacogenomics; the company is working with a Florida institution to advance its technology (known as Ovanome(TM)) and to combine its technology with other genetic methods to help reduce the risk of cancer treatment; and 4) contract genotyping; the company has developed a strong reputation as a reliable and cost-effective contract genotyping service and continues to supply medical centers and universities with this service.
ADVERTISEMENT


"We see the forum as a means to advance our company and improve shareholder value through partnering opportunities that might present themselves at this conference," said Richard Gabriel, CEO and President of DNAPrint(TM) genomics, Inc. "Over the last year we have been relatively quiet. We have spent this time reorganizing the company and advancing our technologies. We are seeking partners in all three commercial areas, genealogy, forensics and pharmacogenomics, and that could include partners in a variety of structures. We have just finished an $8.0 million financing round, and the proceeds from that transaction have been flowing into the company at a steady rate. This is the fuel that we need to build the business and advance the technology, and we are doing that."

"The company's senior management will continue to explore all opportunities, and we believe these partnering forums are a great vehicle for allowing companies to exchange ideas and seek new opportunities," said Hector Gomez, MD, PhD, Chairman of the Board and Chief Medical Officer. "Our joining BioFlorida and being involved with the Sarasota business community is another step in advancing our technology and company," he said.

"Sarasota and the Tampa Bay area are a rapidly emerging biotechnology center, and we were one of the first life-science companies to start up in Sarasota -- well, certainly one of the first genetics companies," said Tony Frudakis, PhD. "We're excited about the partnering opportunities that might exist in our own backyard."

About DNAPrint(TM) genomics, Inc.

DNAPrint(TM) genomics, Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The DNAWitness(TM) and the ANCESTRYbyDNA(TM) analysis is a direct result of focused research by the DNAP research and development team.

In addition, using proprietary human genome research methods, the Company develops pharma-predictive tests for matching patients with drugs based on their genetic constitution, discovers disease genes for the development of new drugs and develops new forensic genomics and consumer genomics testing products. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.

For more information on our genealogical DNA-derived test, ANCESTRYbyDNA(TM) 2.5, visit us on line at www.ancestrybydna.com helping everyone to understand their genetic heritage.

All statements in this press release that are not historical and are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's(TM) products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint(TM) genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's(TM) expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Media and Press Contacts
Richard Gabriel
DNAPrint(TM) genomics, Inc.
CEO/President
[phone]




--------------------------------------------------------------------------------
Source: DNAPrint(TM) genomics, Inc.

Email this story - Set a News Alert